BV regimen pre ASCT #EHA2026 #26

Good morning everyone

1/3 As #EHA2026 wraps up, #multiplemyeloma again feels like a field moving at remarkable speed. But the next leadership question may not be only: “Who can get the deepest MRD negativity?” It may be: “Who can prove when therapy can safely stop?” We have mastered escalation. Now finite therapy must become a science. #MMsm #myeloma

My summary of CARTITUDE4, MajesTEC3, MajesTEC9 and MoumenTAL3. In anti-CD38 refractory patients and EMDs -->TCE anti-BCMA or anti-GPRC5D are >> to Cilta-Cel

CONGRESS | #EHA2026 | PRESENTATION Uma Borate, Ohio State University, US, presents findings from the phase II OPTI-AML trial of 28- vs 14-day schedules of venetoclax azacitidine for 2 cycles in patients aged ≥60 years with ND, genomically agnostic AML (N = 169). After 2 cycles, the CR rates were 49% vs 43% with 28- vs 14-day cycles, respectively. Composite CR rates were 81% vs 69% and MRD-negativity rates were 78% vs 77% in the 28- vs 14-day cycle groups, respectively. The median OS was 21.4 months in the 28-day cycle group vs 13.6 months in the 14-day cycle group, and the median PFS was 9.9 months vs 13.1 months. Grade ≥3 TEAEs and early mortality were similar between groups Follow our live feed for more updates: loom.ly/XyM7Jss Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #AMLsm #MedicalCongress #MedEd #MedNews @beatalleukemia @OhioStateMed

John Mascarenhas presents results of AJX-101 Phase 1 study in R/R MF. Happy to have contributed to this effort @OSUCCC_James with exciting results & slide colors after my own heart.

Endo plenary drugs hormones and cancer @TheEndoSociety

Evidence of Auto SCT in R/R HL #EHA26 #EHA2026

The best TKI for the frontline? #EHA2026

Extraordinary data from Majestec-3 with Tec-dara vs SOC in high-risk / functional high risk pts. Tec-dara is even more so a new SOC at first relapse. Congrats to the team @RahulBanerjeeMD @mvmateos @End_myeloma @AjayNookaMD @NBahlis @PerrotAurore @_DrCP @dra_v_hungria

Based on a recent slew of RCTs & updates at #ASCO26 and #EHA26 in relapsed #MultipleMyeloma, here is my framework for approaching 1st relapse (assuming access to all of these regimens in patients with ≥1 prior LoT). Its an exciting time in myeloma, with a rapidly changing treatment landscape!

AGA and CML prognosis #EHA2026

Should classification impact treatment? #EHA26 #EHA2026

#EHA2026 a new standard of care about to emerge in myeloma! @PlasmaCellPete looking as presidential as ever at the plenary session 💪 MonumenTAL-3: tal-dara /- pom versus Dara-Pd. Tal-DP and tal-D both dramatically outperformed D-Pd!

ASXL1 and role of Asciminib #EHA2026

Donate blood be a Hero There is huge shortage of blood products Blood donation has lots of benefits World Blood Donor Day 2026

5 years from now or 50 years from now patients still want the same: Competent and empathetic physicians who are accessible when the need arises, and affordable care. We cannot wrap stuff with the word “innovation” when the changes in healthcare policies and priorities are reducing the development of clinical excellence, placing barriers to access, increasing cost of care, and accelerating burnout of experienced clinicians.

Which is why I haven’t changed approach to first relapse. With Talq I’m not even sure of second relapse. Best only after refractory to triplet and BCMA. Or as a short term therapy to reduce tumor burden prior to BCMA approaches especially BCMA CART. And in refractory BCMA sensitive EMD relapse with Tec.

TKIs inhibiting BCR::ABL1 #EHA2026

TP53 myeloid neoplasms….. easy to diagnose, breezy to treat ….. 🤥 #EHA2026